Clarence Thomas Building
P.O. Box 4649 Road Town
Tortola VG1110
British Virgin Islands
203 221 7378
https://www.portagebiotech.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 7
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Ian B. Walters M.B.A., M.D. | CEO & Chairman of Board | 967,65k | N/D | 1968 |
Mr. Allan J. Lee Shaw CPA | Chief Financial Officer | 524,08k | N/D | 1964 |
Dr. Robert A. Kramer Ph.D. | Chief Scientific Officer | 310,16k | N/D | N/D |
Mr. Brian Wiley | Chief Business Officer | 220,69k | N/D | 1968 |
Mr. Justin Fairchild | Vice President of Development | 283,83k | N/D | N/D |
Mr. Joseph Ciavarella | Chief Accounting Officer | N/D | N/D | N/D |
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.
L'ISS Governance QualityScore di Portage Biotech Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.